Going Global Weekly: Overseas Pharma Qualifications and Licensing Land in Clusters as Cross-border M&A and Hong Kong Filings Advance in Tandem-20261116
Overseas M&A
1. JD-SW (09618.HK): Announced on November 12 that it has completed its voluntary public takeover offer for CECONOMY AG, a German consumer electronics retail group, through its wholly-owned indirect subsidiary JINGDONG HOLDING GERMANY GMBH at EUR 4.60 in cash per share, for total consideration of EUR 1.335 billion, acquiring 59.8% of the share capital and voting rights; all offer conditions (including merger control approval, foreign investment approval and EU foreign subsidies approval) have been satisfied, and CECONOMY has become a subsidiary and has been consolidated since that date, with the 25.3% stake retained by partner Convergenta bringing the two parties' combined holding to 85.2%. CECONOMY operates more than 1,000 consumer electronics stores in 11 markets under the MediaMarkt, Saturn and MediaWorld brands and employs more than 50,000 people, with more than 53 million loyalty members and 2.2 billion customer contacts in 2025; the company said CECONOMY will maintain independent operations in Europe and its own local technology architecture, with no plans to adjust headcount or office locations.
2. GRAPHEX GROUP (06128.HK): Announced on November 9 that the buyer, M2i Global, Inc., exercised its option after the trading session on November 6, and that the company has entered into a definitive agreement to sell all interests (100 units) in its indirectly wholly-owned subsidiary Graphex Technologies LLC for total consideration of USD 100 million, payable in cash and consideration shares issued in three tranches: USD 30 million at closing, of which USD 3 million is payable by a consideration note maturing on December 31, 2026 and USD 27 million by tranche-one consideration shares at USD 3.00 per share; USD 30 million by tranche-two consideration shares at USD 3.00 per share following delivery and acceptance of the basic design by the buyer; and USD 40 million by tranche-three consideration shares at USD 4.00 per share upon completion of the plant and receipt of production approval (which may be about 36 months after delivery of the basic design). Upon completion, the group will no longer hold any interest in the disposed company.
Overseas Cooperation
1. REMEGEN (09995.HK): Announced on November 12 that it has entered into an amendment agreement to the licence agreement dated June 25, 2025 with Vor Biopharma Inc., bringing its self-developed RC298 into the scope of cooperation, with Vor Bio obtaining exclusive rights to develop and commercialise RC298 worldwide (excluding Greater China) while the company retains all rights in Greater China. The company will receive an upfront payment with a total value of approximately USD 56 million, comprising USD 10 million in cash and warrants to subscribe for 2.30 million shares of Vor Bio common stock (exercise price of USD 0.0001 per share, valued at approximately USD 46 million based on the closing price on November 11), and will be eligible for up to USD 300 million in development milestone payments, of which USD 20 million is payable upon achievement of early clinical development and technology transfer milestones, while the existing sales milestone and royalty mechanisms continue to apply. RC298 is a long-acting dual-target BAFF/APRIL inhibitor and an engineered TACI-Fc fusion protein, currently in the preclinical stage in preparation for an IND filing.
2. XTALPI (02228.HK): Voluntary announcement on November 9 that its wholly-owned subsidiaries QuantumPharm Limited and XtalPi Intelligent Drug Technology (Shanghai) Co., Ltd. entered into a research collaboration agreement with Pierre Fabre Médicament SAS (a member of the Laboratoires Pierre Fabre group) to discover novel clinical candidates across multiple research programmes in oncology, potentially extending to dermatology and rare diseases. The group will apply its integrated AI capabilities and robotic platform to design and deliver novel small-molecule therapies from scratch against undisclosed targets, while Pierre Fabre will contribute expertise in disease biology, drug discovery, translational research and clinical development and will be responsible for subsequent clinical and commercial development. The collaboration includes upfront payments, multiple milestone payments and downstream economic sharing, with the specific amounts not disclosed in the announcement.
Overseas Orders and Bid Wins
1. CHINASOFT INT'L (00354.HK): Voluntary announcement on November 9 that it has recently won an enterprise-level data modernisation total integration project worth hundreds of millions from a leading bank in Southeast Asia. Built on Huawei DWS for migration and transformation, the project covers the establishment of a single trusted enterprise data source, unification of data standards across the whole business, enhancement of data quality, data lineage and security controls, reduction of total IT cost of ownership through architectural iteration, and the creation of a modern data platform supporting AI evolution, while also completing capability enhancements to the core customer information framework (GCIF). The project adopts an integrated hardware-and-software total integration model, and the company described the win as a milestone breakthrough in its overseas financial services track.
Overseas Projects and Operations
1. DEEP SOURCE (00990.HK): Published a supplemental announcement on November 11 regarding the Kuantan AI data centre project. The group entered into a sale and purchase agreement on October 18 to acquire eight parcels of land in Kuantan, Pahang, Malaysia for total consideration of approximately MYR 417.49 million. The project will be developed in two phases, with the first phase giving priority to Plot 1 for an AI data centre; Beibu Gulf Holding (Malaysia) Sdn. Bhd. has issued a formal commitment letter reserving a total of 120 MW of generation capacity for the project, with a construction period of about six to twelve months. The second phase involves the remaining seven parcels, some for data centres and some for supporting power generation facilities. Funding is expected to come from internal resources, net proceeds of approximately HKD 1.299 billion from the disposal of futures and related financial businesses (the transaction has not yet completed), customer prepayments and external financing.
Regulatory and Compliance
1. ABBISKO-B (02256.HK): Disclosed on November 11 that PIMJETMI® (pimicotinib), a CSF-1R small-molecule inhibitor developed by its subsidiary Shanghai Abbisko Therapeutics Co., Ltd., has been approved by the US FDA for the systemic treatment of adult patients with symptomatic tenosynovial giant cell tumour (TGCT) for whom surgical resection may cause worsening functional limitation or severe morbidity. This is the fourth marketing approval for the product, following China in December 2025, Canada in June 2026 and Switzerland in October 2026. The approval was based on the global Phase III MANEUVER study, in which the objective response rate at week 25, assessed by a blinded independent review committee per RECIST v1.1, was 56% versus 3% for placebo (p<0.0001); at a median follow-up of 14.3 months the median duration of response had not been reached, and 77% of patients who achieved a response at week 25 maintained clinical benefit after an additional 12 months of follow-up. Global commercialisation rights have been granted to Merck KGaA, and the company will receive a USD 20 million milestone payment upon the first commercial sale in the United States, together with double-digit percentage royalties on global net sales.
2. WUXI APPTEC (02359.HK): Announced on November 10 that the US Department of Defense has decided to remove the company from the "Chinese military companies" list under Section 1260H, which the company learned of on November 9. The Department of Defense added the company to the list on June 8, 2026; the company filed a lawsuit in the US District Court for the District of Columbia on June 11 and a motion for a preliminary injunction on June 29, and the court held a hearing on July 22 and issued a ruling on August 7; the Deputy Secretary of Defense determined that the court's order granting the preliminary injunction motion should be followed. The company said the decision protects it from further adverse effects of the designation.
3. HANSOH PHARMA (03692.HK): Announced on November 15 that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion on November 12 recommending the granting of an EU marketing authorisation for aumolertinib (overseas brand name Aumseqa®) for the treatment of adults with non-small cell lung cancer. The marketing authorisation remains subject to final approval by the European Commission; the company had previously published announcements on September 27 and October 11 updating the status of the EU marketing authorisation.
4. SIMCERE PHARMA (02096.HK): Announced on November 9 that the independently developed TL1A/IL-23p19 bispecific antibody SIM0709 has been approved by the Paul-Ehrlich-Institut, the German Federal Institute for Vaccines and Biomedicines, and the competent ethics committee to initiate a Phase I clinical trial in healthy participants, with inflammatory bowel disease as the target indication. SIM0709 is being advanced for global development with Boehringer Ingelheim under an exclusive licence agreement signed in January 2026, under which the latter obtained exclusive global rights outside Greater China and the group is entitled to an upfront payment of EUR 42 million and up to EUR 1.016 billion in development, regulatory and commercialisation milestone payments.
5. ASCLETIS-B (01672.HK): Announced on November 11 that it has submitted an investigational new drug (IND) application to the US FDA for ASC30_39 FDC for the treatment of obesity. The drug is a once-daily oral fixed-dose combination of the small-molecule GLP-1R agonist ASC30 and the small-molecule selective amylin receptor agonist ASC39, and is the first oral GLP-1 and oral amylin combination to be filed for an IND. ASC30 is currently being evaluated in two global pivotal Phase III studies (AURORA-1 and AURORA-2) in the United States, Europe and Canada, enrolling approximately 4,600 subjects with obesity or overweight, with topline data expected in the third quarter of 2028.
Overseas Financing
1. TUOPU GROUP (601689.SH): Disclosed on November 9 that it received a notice of filing for overseas issuance and listing from the China Securities Regulatory Commission (Guohehan [2026] No. 2553), proposing to issue no more than 272,524,100 ordinary shares for overseas listing and to list on the Main Board of the Hong Kong Stock Exchange. The offering remains subject to approval by the Securities and Futures Commission of Hong Kong and the Stock Exchange and is subject to uncertainty; the company must report the issuance and listing through the filing management information system within 15 working days after completion.
2. CAPCHEM (300037.SZ): On November 13, the International Cooperation Department of the China Securities Regulatory Commission disclosed that its overseas issuance and listing has been filed, with the company proposing to issue no more than 96,329,900 ordinary shares for overseas listing and to list on the Hong Kong Stock Exchange.
3. Zhejiang Energy Marine Environmental Technology: On November 13, the International Cooperation Department of the China Securities Regulatory Commission disclosed that the overseas issuance and listing of Zhejiang Energy Marine Environmental Technology Co., Ltd. has been filed, with the company proposing to issue no more than 64,687,500 ordinary shares for overseas listing and to list on the Hong Kong Stock Exchange.
4. PUYA SEMICONDUCTOR (688766.SH): Announced on November 11 that it is planning an overseas issuance of shares (H shares) and a listing on the Hong Kong Stock Exchange to advance its globalisation strategy and overseas business layout. Relevant details have not yet been determined, and the plan will not result in a change of controlling shareholder or actual controller; it remains subject to deliberation by the board and the shareholders' meeting and to approval or filing by the China Securities Regulatory Commission, the Stock Exchange and the Securities and Futures Commission of Hong Kong.
5. KFMI (300666.SZ): Submitted an application on November 12 for a Main Board listing on the Hong Kong Stock Exchange, with CMS International as sole sponsor. According to Frost & Sullivan, the company ranked second among global ultra-high purity metal sputter target suppliers by revenue for four consecutive years from 2022 to 2025, with a 10.3% global market share in 2025 and a 14.9% share of the global market for targets used in semiconductor chips; it is the first Chinese company certified to supply targets to all of the global top ten IDMs and top ten wafer foundries, and held 1,085 valid granted patents worldwide as at the latest practicable date.
6. TRANSSION (02636.HK): Announced on November 11 that the overall coordinator partially exercised the over-allotment option on that day in respect of 6,500,600 H shares, representing approximately 7.50% of the total number of shares under the global offering, at HKD 35.30 per share, raising additional net proceeds of approximately HKD 227.1 million, with the shares expected to commence trading on the Main Board of the Stock Exchange on November 16; the stabilisation period ended on the same day, during which the stabilising manager, CLSA, purchased 6,496,600 shares at prices ranging from HKD 32.36 to HKD 35.30 per share, and the unexercised portion lapsed on the same day.
7. BANK OF CHINA (03988.HK): Announced on November 12 that its Sydney Branch has issued AUD 400 million floating rate notes due 2031 and RMB 2 billion 1.64% notes due 2029 under its USD 40 billion Medium Term Note Programme, and has applied to the Stock Exchange for listing of the debt securities by way of issuance to professional investors only, expected to become effective on November 13. The pricing supplement is dated November 4, and the notes have not been and will not be registered under the US Securities Act of 1933.
Overseas Operating Data
1. SINOMAX GROUP (01418.HK): Voluntary announcement on November 10 clarifying the basis for classifying regional revenue: retail sales revenue is classified by the location of retail stores and consignment counters, and wholesale sales revenue by customers' billing addresses, so sales to customers in the Chinese mainland and Hong Kong, Macao and Vietnam are attributed to those regions regardless of whether the products are subsequently distributed to other markets. According to supplementary information confirmed in writing by customers, revenue attributable to the Chinese mainland in 2025 was HKD 1.5216 billion and that attributable to the United States was HKD 1.5507 billion; after including products subsequently distributed to the United States from the Chinese mainland and other regions, revenue in the US end market was approximately HKD 1.9326 billion, while the Chinese mainland, net of such distribution, was HKD 1.2323 billion. The group has operated its US business through Sinomax USA since 2005 and completed an increase in its stake in Denmark's MDK Holdings ApS to 55% in August 2025.
NewTimeSpace Going Global Observation
This week's overseas expansion narrative was shaped by two threads: the acquisition of qualifications and licensing transactions on the pharmaceutical side, and cross-border equity moves on the consumer and manufacturing side. The former spans marketing approvals, positive opinions and clinical clearances for innovative drugs in the United States, the European Union and Germany, and also includes licensing and co-development arrangements with overseas pharmaceutical companies covering bispecific antibodies, AI-driven drug discovery and siRNA platforms, with the overseas credential shifting from sales rights for a single product to platform capability. The latter is represented by the outright acquisition of a consumer electronics retailer and the full disposal of a new materials subsidiary, with buying and selling occurring within the same week, reflecting companies' adjustment of their European and North American asset portfolios in line with their own strategies. Meanwhile, the pace of CSRC filings and listing applications by A-share companies for Hong Kong continued, note issuance by overseas branches resumed, and cross-border arrangements on both the funding and asset sides advanced in tandem. Compared with the earlier focus on pipeline licensing, this week's pharmaceutical overseas expansion was more about actual regulatory review milestones, moving from submission and acceptance towards approval and commercialisation preparation.
This article is for information purposes only and does not constitute any investment advice.
- Going Global Weekly: Pharma Licensing and Overseas Registrations Land in Clusters as Overseas and Secondary Listings Advance Together-20261108
- Going Global Weekly: Innovative Drug Data and Regulatory Qualifications Go Global in Clusters as Tech IPOs See Pricing and Terminations Side by Side-20261030
- Going Global Weekly: Pharma Out-Licensing Deals Land in Succession as the A-Share Hong Kong Listing Pipeline Expands-20261023
- Going Global Weekly: Pharmaceutical Compliance Qualifications and Overseas Orders Land Densely, Hong Kong Fundraising and Offshore Bond Issuance Accelerate in Tandem-20261016
- Going Global Weekly: Mainland Companies Flock to Hong Kong Listings, Pharma Globalisation Shifts to Data and Capability Export-20260918